Prospective Study of Pravastatin in Elderly People at Risk (PROSPER)
Jump to navigation
Jump to search
Introduction
Epidemiologic study ongoing in 2001 in Scotland, Ireland & the Netherlands.
Patient population:
- 5000-6000 men & women with vascular disease or risk factors for cardiovascular disease, aged 70-82 years
Study monitors:
Pravastatin 40 mg/day vs placebo
Results:
- average follow-up of 3 years
- mean cholesterol level 147 mg/dL lowered by 38% in pravastatin group
- combined endpoint myocardial infarction & stroke (fatal & non-fatal) significantly lower in pravastatin group (14.1% vs 16.2%)
- myocardial infarction significantly reduced, but stroke was NOT
- cognition & disability NOT significantly affected
- new cancers occurred significantly more often in the pravastatin group
More general terms
Additional terms
References
- ↑ Marx J. Science 294:508, 2001
- ↑ Journal Watch 23(3):23, 2003 Shepherd J et al, Pravstatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 36:1623, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12457784 Collins R & Armitage J, High risk elderly patients PROSPER from cholesterol-lowering therapy. Lancet 360:1618, 2002 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/12457780 <Internet> http://www.thelancet.com/journal/vol360/iss9346/full/llan.360.9346.original_research.23196.1